PMID- 35920616
OWN - NLM
STAT- MEDLINE
DCOM- 20220930
LR  - 20221015
IS  - 1747-4094 (Electronic)
IS  - 1747-4094 (Linking)
VI  - 15
IP  - 9
DP  - 2022 Sep
TI  - Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with 
      chronic lymphocytic leukemia: a meta-analysis and systematic review.
PG  - 849-856
LID - 10.1080/17474086.2022.2110062 [doi]
AB  - BACKGROUND: Phosphatidylinositol 3-kinase (PI3K) inhibitors demonstrate promising 
      effects in the treatment of relapsed/refractory chronic lymphocytic leukemia 
      (CLL). Emerging evidence of the therapeutic effects of the PI3K inhibitors in 
      various aspects remains controversial. RESEARCH DESIGN AND METHODS: This 
      meta-analysis was used to evaluate the efficacy and safety of PI3K inhibitors 
      based on a synthesis of the data generated by randomized controlled trials (RCTs) 
      of patients with CLL, by searching PubMed, EMBASE, Cochrane Central Register of 
      Controlled Trials, and ClinicalTrials.gov registry. RESULTS: Five RCTs with 1593 
      patients were included. The PI3K inhibitors significantly improved 
      progression-free survival (PFS), the chance of overall response, and partial 
      response compared to the control arm. Regarding adverse events (AEs), the PI3K 
      inhibitors increased the risk of pyrexia, chills, diarrhea, decreased appetite, 
      vomiting, rash, pneumonia, and upper respiratory tract infection. CONCLUSIONS AND 
      EXPERT OPINION: Available evidence showed significant improvements over 
      conventional therapy in PFS of the PI3K inhibitors in patients with CLL, with 
      relatively manageable AEs.
FAU - Wen, Yanting
AU  - Wen Y
AD  - Department of Basic Medicine, Center of Translational Medicine, Jiangsu Key 
      Laboratory of Molecular Medicine, Nanjing University Medical School, Nanjing, 
      Jiangsu, China.
FAU - Meng, Li
AU  - Meng L
AD  - Maternity Intensive Care Unit, Nanjing Maternity and Child Health Care Hospital, 
      Women's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
FAU - Zhang, Xian
AU  - Zhang X
AD  - Department of Basic Medicine, Center of Translational Medicine, Jiangsu Key 
      Laboratory of Molecular Medicine, Nanjing University Medical School, Nanjing, 
      Jiangsu, China.
FAU - Gao, Qian
AU  - Gao Q
AD  - Department of Basic Medicine, Center of Translational Medicine, Jiangsu Key 
      Laboratory of Molecular Medicine, Nanjing University Medical School, Nanjing, 
      Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220809
PL  - England
TA  - Expert Rev Hematol
JT  - Expert review of hematology
JID - 101485942
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
MH  - Phosphatidylinositol 3-Kinases
MH  - Phosphoinositide-3 Kinase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Phosphatidylinositol 3-kinase inhibitor
OT  - chronic lymphocytic leukemia
OT  - meta-analysis
OT  - randomized controlled trial
OT  - systematic review
EDAT- 2022/08/04 06:00
MHDA- 2022/10/01 06:00
CRDT- 2022/08/03 08:43
PHST- 2022/08/04 06:00 [pubmed]
PHST- 2022/10/01 06:00 [medline]
PHST- 2022/08/03 08:43 [entrez]
AID - 10.1080/17474086.2022.2110062 [doi]
PST - ppublish
SO  - Expert Rev Hematol. 2022 Sep;15(9):849-856. doi: 10.1080/17474086.2022.2110062. 
      Epub 2022 Aug 9.